Study of the reversal effect of NF449 on neuromuscular blockade induced by d-tubocurarine

Life Sciences

Volumn 88, Issue 23-24, 2011, Pages 1039-1046

  Su, Tzu Rong ^a   Hung, Yu Shiang ^b   Huang, Shiang Suo ^b   Su, Hsing Hui ^b   Su, Ching Chyuan ^a   Hsiao, George ^c   Chen, Yi Hung ^d   Lin, Min Jon ^b,e  

^a TIAN SHENG MEMORIAL HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

D tubocurarine; Neuromuscular blockade reversal agents; NF449; Nicotinic acetylcholine receptor; Purinoceptors; Suramin analogues

Indexed keywords

ACETYLCHOLINE; NF 007; NF 023; NF 279; NF 449; SURAMIN; TUBOCURARINE CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; ENDPLATE POTENTIAL; MINIATURE ENDPLATE POTENTIAL; MOUSE; MUSCLE CONTRACTION; NERVE STIMULATION; NEUROMUSCULAR BLOCKING; NONHUMAN; PRESYNAPTIC NERVE;

ACETYLCHOLINE; ANIMALS; BENZENESULFONATES; BINDING, COMPETITIVE; CHICKENS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; EXCITATORY POSTSYNAPTIC POTENTIALS; MICE; MICE, INBRED ICR; MUSCLE CONTRACTION; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS; PROTEIN BINDING; RECEPTORS, NICOTINIC; SURAMIN; TUBOCURARINE;

EID: 79957555014     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2011.03.013     Document Type: Article

References (36)

1. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 2009;89(1):73-120.
2. Azam L, McIntosh JM. Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors. Acta Pharmacol Sin 2009;30(6):771-83.
3. Barstad JA, Lilleheil G. Transversely cut diaphragm preparation from rat, an adjuvant tool in the study of the physiology and pbarmacology of the myoneural junction. Arch Int Pharmacodyn Ther 1968;175(2):373-90.
4. Beindl W, Mitterauer T, HoheneggerM, Ijzerman AP, Nanoff C, Freissmuth M. Inhibition of receptor/G protein coupling by suramin analogues. Mol Pharmacol 1996;50(2): 415-23. (Pubitemid 26265148)
5. Braun K, Rettinger J, Ganso M, Kassack M, Hildebrandt C, Ullmann H, et al. NF449: a subnanomolar potency antagonist at recombinant rat P2X1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2001;364(3):285-90. (Pubitemid 32802159)
6. Damer S, Niebel B, Czeche S, Nickel P, Ardanuy U, Schmalzing G, et al. NF279: a novel potent and selective antagonist of P2X receptor-mediated responses. Eur J Pharmacol 1998;350(1):R5-6.
7. Dhar S, Gullbo J, Csoka K, Eriksson E, Nilsson K, Nickel P, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer 2000;36(6):803-9. (Pubitemid 30179754)
8. Dunn PM, Blakeley AG. Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol 1988;93(2):243-5. (Pubitemid 18042809)
9. Fagerlund MJ, Eriksson LI. Current concepts in neuromuscular transmission. Br J Anaesth 2009;103(1):108-14.
10. Gill JS, Connolly DC, McManus MJ, Maihle NJ, Windebank AJ. Suramin induces phosphorylation of the high-affinity nerve growth factor receptor in PC12 cells and dorsal root ganglion neurons. J Neurochem 1996;66(3):963-72. (Pubitemid 26065892)
11. Ginsborg BL, Warriner J. The isolated chick biventer cervicis nerve-muscle preparation. Br J Pharmacol Chemother 1960;15:410-1.
12. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 2010;20(5):625-46.
13. Henning RH, Nelemans A, Houwertjes M, Agoston S. Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. Br J Pharmacol 1993;108(3):717-20. (Pubitemid 23067942)
14. Henning RH, Rowan EG, Braga MF, Nelemans A, Harvey AL. The prejunctional inhibitory effect of suramin on neuromuscular transmission in vitro. Eur J Pharmacol 1996;301(1-3):91-7. (Pubitemid 26169746)
15. Hohenegger M, Waldhoer M, Beindl W, Boing B, Kreimeyer A, Nickel P, et al. Gsalpha-selective G protein antagonists. Proc Natl Acad Sci USA 1998;95(1): 346-51.
16. Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 2010;86(15-16):575-84.
17. Huh KH, Fuhrer C. Clustering of nicotinic acetylcholine receptors: from the neuromuscular junction to interneuronal synapses. Mol Neurobiol 2002;25(1): 79-112. (Pubitemid 34165506)
18. Hülsmann M, Nickel P, Kassack M, Schmalzing G, Lambrecht G, Markwardt F. NF449, a novel picomolar potency antagonist at human P2X1 receptors. Eur J Pharmacol 2003;470(1-2):1-7. (Pubitemid 36638618)
19. Inoue K, Nakazawa K, Ohara-Imaizumi M, Obama T, Fujimori K, Takanaka A. Selective and competitive antagonism by suramin of ATP-stimulated catecholaminesecretion from PC12 phaeochromocytoma cells. Br J Pharmacol 1991;102(3): 581-4.
20. Jentsch KD, Hunsmann G, Hartmann H, Nickel P. Inhibition of human immunodeficiency virus type I reverse transcriptase by suramin-related compounds. J Gen Virol 1987;68(Pt 8):2183-92.
21. Kassack MU, Braun K, Ganso M, Ullmann H, Nickel P, Böing B, et al. Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem 2004;39(4): 345-57. (Pubitemid 38457028)
22. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, et al. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem 2010;285(27): 20644-53.
23. Lin-Shiau SY, Lin MJ. Studies on curare-like action of the tripeptide carbobenzoxy-Gly-Gly-Arg-beta-naphthylamide in mouse diaphragm. Eur J Pharmacol 1998;343(1): 51-6.
24. Mallart A. Electric current flow inside perineurial sheaths of mouse motor nerves. J Physiol 1985;368:565-75. (Pubitemid 16192437)
25. McArdle JJ, Angaut-Petit D, Mallart A, Bournaud R, Faille L, Brigant JL. Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena. J Neurosci Methods 1981;4(2):109-15. (Pubitemid 11005369)
26. Miledi R, Potter LT. Acetylcholine receptors in muscle fibres. Nature 1971;233(5322): 599-603.
27. Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, et al. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma. Br J Cancer 2005;92(12):2140-7. (Pubitemid 40966248)
28. Rettinger J, Schmalzing G, Damer S, Müller G, Nickel P, Lambrecht G. The suramin analogue NF279 is a novel and potent antagonist selective for the P2X1 receptor. Neuropharmacology 2000;39(11):2044-53. (Pubitemid 30645628)
29. Schneider J. Treatment of African trypanosomiasis (sleeping sickness). Presse Med 1960;68:881-3.
30. Schulz-Key H, Karam M, Prost A. Suramin in the treatment of onchocerciasis: the efficacy of low doses on the parasite in an area with vector control. Trop Med Parasitol 1985;36(4):244-8. (Pubitemid 16177100)
31. Soto F, Lambrecht G, Nickel P, Stühmer W, Busch AE. Antagonistic properties of the suramin analogue NF023 at heterologously expressed P2X receptors. Neuropharmacology 1999;38(1):141-9. (Pubitemid 29073533)
32. Su TR, Chen CH, Huang SJ, Lee CY, Su MC, Chen GH, et al. Functional study of the effect of phosphatase inhibitors on KCNQ4 channels expressed in Xenopus oocytes. Acta Pharmacol Sin 2009;30(9):1220-6.
33. Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, et al. Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency. J Med Chem 2005;48(22):7040-8. (Pubitemid 41533126)
34. Van Rhee AM, van der Heijden MPA, Beukers MW, Ijzerman AP, Soudijn W, Nickel P. Novel competitive antagonists for P2 purinoceptors. European J Pharmacology Molecular Pharmacology 1994;268(1):1-7. (Pubitemid 2104692)
35. Villalona-Calero MA, Otterson GA, Wientjes MG, Weber F, Bekaii-Saab T, Young D, et al. Noncytotoxic suramin as a chemosensitizer in patients with advanced nonsmall- cell lung cancer: a phase II study. Ann Oncol 2008;19(11):1903-9.
36. Zouridakis M, Zisimopoulou P, Poulas K, Tzartos SJ. Recent advances in understanding the structure of nicotinic acetylcholine receptors. IUBMB Life 2009;61(4):407-23.